#biotech

📊Earnings 📈 Stocks

Corbus Pharmaceuticals Reports Q3 2026 Net Loss of $37.8 Million

November 10, 2026 (3 hours ago)

Corbus Pharmaceuticals posted a $37.8 million Q3 2026 net loss amid a $15.0 million milestone payment, while maintaining $115.3 million in cash…

CRBP

🌍 US Read More →

📊Earnings 📈 Stocks

Hemab Therapeutics Initiates Pivotal Phase 3 SOLARA Trial for Sutacimig

November 10, 2026 (5 hours ago)

Hemab Therapeutics advances its clinical pipeline with the start of a pivotal Phase 3 trial for sutacimig and reports positive early-stage data…

COAG

🌍 US Read More →

🏢Release 📈 Stocks

MaxCyte to Acquire Akron Bio for $151.8 Million to Double Revenue Base

November 10, 2026 (5 hours ago)

MaxCyte will acquire Akron Bio for $151.8 million, utilizing a mix of cash, stock, and a new $75.0 million credit facility to…

MXCT

🌍 US Read More →

🏢Release 📈 Stocks

Ribo Life Science Files EU Clinical Trial Application for siRNA Drug SR122

November 10, 2026 (11 hours ago)

Ribo Life Science advances its lipid-disorder pipeline with an EU Phase I trial application for SR122, a dual-target siRNA candidate targeting ApoC3…

06938.HK

🌍 GLOBAL Read More →

📊Earnings 📈 Stocks

Rani Therapeutics Reports $8.8 Million Q3 Loss, Joins FDA Tech Program

November 9, 2026 (19 hours ago)

Rani Therapeutics posted a $8.8 million Q3 net loss while securing FDA Emerging Technology Program acceptance and reporting $45.3 million in liquidity…

RANI

🌍 US Read More →

📊Earnings 📈 Stocks

GeneDx Holdings Q3 Revenue Hits $123.1M as Growth Targets Are Trimmed

November 9, 2026 (19 hours ago)

GeneDx Holdings posted a widened net loss of $(12.3) million for the third quarter of 2026, even as it maintained its annual…

WGS

🌍 US Read More →

🏛️Filing 📈 Stocks

Orchestra BioMed Announces Proposed Common Stock Offering

November 9, 2026 (19 hours ago)

Orchestra BioMed is launching a public offering of common stock to finance its pivotal clinical trials, with underwriters holding a 30-day option…

OBIO

🌍 US Read More →

🏛️Filing 📈 Stocks

Rafael Holdings Submits Remibetadex NDA Following Phase 3 TransportNPC Study

November 9, 2026 (19 hours ago)

Rafael Holdings submitted an NDA for remibetadex in October 2026 after a Phase 3 study showed a 71% slowing of disease progression…

RFL

🌍 US Read More →

🏢Release 📈 Stocks

Zealand Pharma's Survodutide Hits Primary Endpoint in Phase 3 CVOT Trial

November 9, 2026 (1 day ago)

Survodutide met its primary cardiovascular safety endpoint in the Phase 3 SYNCHRONIZE-CVOT trial, showing significant cardiometabolic benefits including weight loss of up…

ZEAL

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Eli Lilly's Foundayo Hits Primary Endpoint in Phase 3 Sleep Apnea Trial

November 9, 2026 (1 day ago)

Eli Lilly's Foundayo met primary endpoints in the ATTAIN-OSA trial, showing significant reductions in sleep apnea severity and body weight, with an…

LLY

🌍 US Read More →

🏢Release 📈 Stocks

Viking Therapeutics to Present VK2735 Data at ObesityWeek 2026

November 9, 2026 (1 day ago)

Viking Therapeutics will showcase data on its lead obesity candidate, VK2735, during two poster sessions at the ObesityWeek 2026 conference held from…

VKTX

🌍 US Read More →

🏢Release 📈 Stocks

XtalPi Partners With Laboratoires Pierre Fabre for AI Drug Discovery

November 9, 2026 (1 day ago)

XtalPi (2228.HK) and Laboratoires Pierre Fabre have entered a drug discovery partnership utilizing AI and robotics to target oncology and rare diseases,…

2228.HK

🌍 ASIA Read More →